Reason for request
Extension of indication
Clinical Benefit
| Substantial |
Substantial in the treatment of SJIA. |
Clinical Added Value
| moderate |
Like ROACTEMRA (tocilizumab), ILARIS (canakinumab) provides a moderate improvement in actual benefit (level III) in the management of patients aged 2 years and older, with active systemic juvenile idiopathic arthritis, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. |
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
CENAYL33p6NvLWug
